These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17096953)

  • 1. [Amifostine in treatment of five patients with myelodysplastic syndrome].
    Qian HL; Shen ZJ; Hu XD; Hu YX; Yu K
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Oct; 24(10):622-3. PubMed ID: 17096953
    [No Abstract]   [Full Text] [Related]  

  • 2. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
    Schanz J; Jung H; Wörmann B; Gassmann W; Petersen T; Hinke A; Haase D
    Leuk Res; 2009 Sep; 33(9):1183-8. PubMed ID: 19411105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
    Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
    Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
    Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
    Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanism and problem of amifostine in treating myelodysplastic syndromes].
    Dang YH; Li W; Yang B; Zhu HL; Huang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1597-601. PubMed ID: 20030955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amifostine used in the treatment of patients with myelodysplastic syndrome].
    Li SX; Zhu HL; Lu XC; Fan H; Yao SQ; Ma J; Yang QM; Cai LL; Zhuang XM; Yang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):86-90. PubMed ID: 17490528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine in the treatment of patients with myelodysplastic syndrome.
    Larsen SR; Manoharan A
    Aust N Z J Med; 1999 Oct; 29(5):753-4. PubMed ID: 10630666
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
    Invernizzi R; Pecci A; Travaglino E; Gobbi PG; Malabarba L; Ramajoli I; Ascari E
    Br J Haematol; 2002 Jul; 118(1):246-50. PubMed ID: 12100155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
    Lu XC; Zhu HL; Yao SQ; Fan H; Zhuang XM; Yang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):440-2. PubMed ID: 15972137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with myelodysplastic syndrome with amifostine.
    Galanopoulos A; Kritikou-Griva E; Gligori J; Michalis E; Grigoraki V; Marinakis T; Kakkas J; Tasiopoulou A; Anagnostopoulos NI
    Leuk Res; 2001 Aug; 25(8):665-71. PubMed ID: 11397471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndrome in children: changing definitions from FAB 1976 to WHO 2008 classification systems.
    Ravindranath Y
    Pediatr Blood Cancer; 2011 Dec; 57(7):1098-9. PubMed ID: 21793183
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121).
    Mathew P; Gerbing R; Alonzo TA; Wallas T; Gong JZ; Jasty R; Jorstad DT; Raimondi SC; Chavez CM; Eisenberg NL; Hirsch B; Gamis A; Smith FO; Arceci RJ
    Pediatr Blood Cancer; 2011 Dec; 57(7):1230-2. PubMed ID: 21681928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS?
    List AF
    Leuk Res; 1998 May; 22 Suppl 1():S7-11. PubMed ID: 9734693
    [No Abstract]   [Full Text] [Related]  

  • 14. Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients.
    Bowen DT; Denzlinger C; Brugger W; Culligan D; Gelly K; Adlakha S; Groves M; Hepburn M; Kanz L
    Br J Haematol; 1998 Dec; 103(3):785-7. PubMed ID: 9858231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Personal experience in the treatment of the myelodysplastic syndromes].
    Neuwirtová R; Steruská M; Lukásová M; Háber J; Cieslar P; Kvasnicka J
    Vnitr Lek; 1987 May; 33(5):453-62. PubMed ID: 3604066
    [No Abstract]   [Full Text] [Related]  

  • 16. Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide.
    Meers S; Boon L; Verhoef G; Delforge M
    Am J Hematol; 2009 Nov; 84(11):769-70. PubMed ID: 19802880
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
    Tamburini J; Elie C; Park S; Beyne-Rauzy O; Gardembas M; Berthou C; Mahe B; Sanhes L; Stamatoullas A; Vey N; Aouba A; Slama B; Quesnel B; Vekhoff A; Sotto JJ; Vassilief D; Al-Nawakil C; Fenaux P; Dreyfus F; Bouscary D;
    Leuk Res; 2009 Apr; 33(4):547-50. PubMed ID: 18640718
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.
    Latagliata R; Oliva EN; Volpicelli P; Carmosino I; Breccia M; Vincelli I; Alati C; Napoleone L; Vozella F; Nobile F; Alimena G
    Acta Haematol; 2008; 120(2):104-7. PubMed ID: 18974634
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalidomide therapy in adult patients with myelodysplastic syndrome: a north central cancer treatment group phase II trial.
    Musto P
    Cancer; 2007 Mar; 109(6):1211-2; author reply 1212. PubMed ID: 17279582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.